Predicting factors for locoregional failure of high-dose-rate brachytherapy for early-stage oral cancer. (November 2012)

• Record Type: Journal Article
• Authors: Petera, Jiří; Sirák, Igor; Tuček, Luboš; Hodek, Miroslav; Paluska, Petr; Kašaová, Linda; Paulíková, Simona; Vošmik, Milan; Doležalová, Helena; Cvanova, Michaela; Halamka, Magdalena; Laco, Jan
• Is Part Of: Personalized medicine. Volume 9:Number 8(2012)
• Page Start: 879
• Page End: 887
• Publication Date: 2012-11
• Subjects: high-dose-rate brachytherapy -- oral cancer -- predictive factors -- VEGF; Pharmacogenomics -- Periodicals; Pharmacogenetics -- Periodicals; 615.19
• DOI: 10.2217/pme.12.95
• Languages: English
• ISSNs: 1741-0541

Abstract

Aim: Brachytherapy is an alternative to surgery in the treatment of the early stages of oral tongue cancer. The aim of this retrospective study was to analyze the clinical risk factors and possible candidate biomarkers of local and regional tumor control.Patients & methods: Twenty-four patients were treated between the years 2001 and 2010. Median follow-up was 37.4 months. Correlation between disease-free survival and clinical stage, tumor grade, resection margin, depth of invasion, and p16, EGF receptor, NF-κB, HIF-1α, HER2, Ku-80, COX-2 and VEGF expression was evaluated.Results: The estimated 5-year local control was 81% and locoregional control was 62%. Depth of tumor invasion (p = 0.018) and higher VEGF expression (p = 0.016) were significantly predictive for worse disease-free survival in Cox multivariate analysis.Conclusion: Intensity of VEGF expression and depth of tumor invasion may be significantly negative predictors of disease-free survival in tongue cancer patients treated by brachytherapy alone. Predictive value of VEGF deserves evaluation in larger studies.